Introduction
The 32nd Annual San Antonio Breast Cancer Symposium held December 9-13, 2009 provided a comprehensive review of the state of breast cancer research and treatment today and explored promising leads for future research and development. Highlights of newly reported data further disseminate scientific advancement, knowledge, and insight gained from this international scientific symposium.
Featured Content
• Endocrine Therapy
• VEGF-Inhibitor Incorporation into Chemotherapy Regimens
• Multi-Kinase Inhibitor-Containing Regimens
• HER2 Targeted Regimens
• Novel Agents
Editors
William J. Gradishar, MD, bio | Christy A. Russell, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: February 10, 2010 | Expiration date: February 9, 2011
Statement of Need
In 2009, breast cancer remained the number one diagnosed cancer and second-leading cause of
cancer-related deaths in US women. An estimated 192,310 new cases of invasive breast cancer will be diagnosed and 40,170 women will die from this disease. Following the two-decade rise that began in the 1980s, the incidence rate for breast cancer decreased by 3.5% a year from 2001-2004. It has been postulated that this may be related to the reduction in the use of hormone replacement therapy and the adoption of mammography screening. Fortunately, the death rate for women with breast cancer has also declined by about 20% from 1991 (32.69 deaths per 100,000) to 2003 (25.19 deaths per 100,000). It is estimated that 15% of the decline in breast cancer mortality was due to screening mammography and 19% was related to adjuvant treatments. Significant improvements have occurred in the management of women with breast cancer although many questions remain. As clinicians encounter these patients in practice and need to make informed decisions about controversial treatment topics, discussion and debate of these issues are necessary to improve the long-term outcomes of these patients. Continuing medical education programs are important vehicles to assist in the timely distribution and application of this key information in order to improve patient outcomes.
Target Audience
The target audience for this program includes oncologists and other healthcare professionals involved in the treatment of breast cancer.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Incorporate clinical data describing new therapeutic agents or strategies into clinical practice to improve pathologic response rates in patients in the neoadjuvant therapy setting
- Discuss updated efficacy and toxicity data for adjuvant therapy options used in the early breast cancer setting
- Describe the strengths and weaknesses of significant clinical trials of agents designed to improve response and survival rates in the metastatic breast cancer setting
- Explain the implications of genetic analysis and biomarkers on treatment selection and response as they currently relate to patients with breast cancer
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 0199-0000-10-005-H01-P).
|
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 10, 2010 through February 9, 2011, participants must
1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE
Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Abraxis BioScience,
Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc., and
Genentech BioOncology. |
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
William J. Gradishar, MD
Grants/Research Support
Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.
Christy A. Russell, MD
Speakers’ Bureau
AstraZeneca, Genentech BioOncology, GlaxoSmithKline, Novartis,
Pfizer Inc., Roche
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
ACKNOWLEDGEMENT
The editors wish to thank Java Solis, a paid medical writer, for assistance in writing this document.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
|
